医薬品開発における次世代シーケンシング (NGS) の世界市場

世界の医薬品開発における次世代シーケンシング (NGS) の市場規模は、2023年の13億米ドルから、17.7%のCAGRで推移し、2028年には29億米ドルの規模に成長すると予測されています。

地域別で見ると、北米市場が2023年の5億3,980万米ドルから、18.0%のCAGRで推移し、2028年には12億米ドルの規模に成長すると予測されています。また、アジア太平洋市場は、2023年の3億1,100万米ドルから、19.0%のCAGRで推移し、2028年には7億4,360万米ドルの規模に成長すると予測されています。

当レポートでは、世界の医薬品開発における次世代シーケンシング (NGS) の市場を調査し、市場および技術の概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、ESGの展開、技術・特許の動向、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

• 技術の背景
• DNAの構造と重要性
• DNAシーケンシング技術
• 全ゲノムシーケンシング
• ターゲットリシーケンシング
• ChiPシーケンシング
• RNAシーケンシング
• メチル化シーケンシング
• DNAシーケンシングの歴史
• サンガーシーケンシング
• 次世代シーケンシング (NGS) の概要
• NGSの利点
• Roche 454 Pyrosequencing
• Illumina NGS
• Thermo Fisher Scientific (Life Technologies) NGS
• シーケンシング機器
• ベンチトップシーケンサー
• インフォマティクス技術
• 医薬品開発におけるNGS
• NGSサービスプロバイダー

第4章 市場力学

• 市場促進要因
• NGS技術を活用したR&D活動の拡大
• 医療費の増加
• シーケンシングプラットフォームにおける技術の進歩
• 精密医療への移行
• 癌患者への個別化医療を設計するためのNGSの需要の高まり
• 高精度・低コスト
• 市場抑制要因
• NGS技術に関連する制約
• クリニカルシーケンシング技術のその他の課題
• 市場機会
• NGSにおけるR&Dの高まりにより、メーカーに有利な機会が生まれる

第5章 医薬品開発におけるNGS市場：製品タイプ別

• 機器
• 消耗品
• サービス

第6章 医薬品開発におけるNGS市場：エンドユーザー別

• 製薬およびバイオテクノロジー企業
• 学術研究センター
• その他

第7章 医薬品開発におけるNGS市場：地域別

• 市場概要・ディスカッション
• 北米
• アジア太平洋
• 欧州
• その他の地域

第8章 医薬品開発NGSにおける持続可能性：ESGの観点

• ESG：概要
• 医薬品開発NGSにおける持続可能性：ESGの観点
• ESGの主要課題
• ESGに対する消費者の態度
• 業界のESGパフォーマンス分析
• ケーススタディ
• 環境
• 社会
• ガバナンス
• BCCによる総論

第9章 新たな技術と開発

• 概要
• 市場における新興技術
• NGSにおけるAIの応用
• 単分子のリアルタイムシーケンシング
• ナノポア技術
• 顕微鏡ベースのシーケンシング

第10章 特許分析

第11章 M&Aと資金調達の見通し

第12章 競合情勢

• 世界企業ランキング
• 世界企業ランキング：機器
• 世界企業ランキング：消耗品
• 世界企業ランキング：サービス

第13章 企業プロファイル

• 10X GENOMICS
• AGILENT TECHNOLOGIES INC.
• BGI (BEIJING GENOMICS INSTITUTE)
• BIO-RAD LABORATORIES INC.
• CD GENOMICS
• ILLUMINA INC.
• INTEGRATED DNA TECHNOLOGIES INC.
• MICRONOMA
• NEW ENGLAND BIOLABS
• OXFORD NANOPORE TECHNOLOGIES
• PACIFIC BIOSCIENCES OF CALIFORNIA INC.
• PERKINELMER INC.
• PROMEGA CORP.
• PSOMAGEN INC.
• PRECISION FOR MEDICINE (旧APOCELL)
• QIAGEN
• ROCHE HOLDING AG
• THERMO FISHER SCIENTIFIC INC.
• TAKARA BIO INC.
• TECAN GROUP LTD.

第14章 付録：頭字語

List of Tables

• Summary Table : Global Market for NGS in Drug Development, by Region, Through 2028
• Table 1 : DNA Translation and Transcription
• Table 2 : Long-range DNA Structure
• Table 3 : DNA Sequencing Workflow
• Table 4 : DNA Sequencing Historical Timeline, 1955-2017
• Table 5 : Sequencing Technology Development, 1990-2020+
• Table 6 : Cost to Sequence a Single Human Genome, 2001-2018
• Table 7 : Sanger Sequencing Summary
• Table 8 : Sanger Sequencing Improvements
• Table 9 : NGS Technologies
• Table 10 : Roche NGS Workflow
• Table 11 : Illumina NGS Workflow
• Table 12 : Thermo Fisher NGS Workflow
• Table 13 : NGS Instruments
• Table 14 : Benchtop and Handheld Sequencer Platforms
• Table 15 : Characteristics of NGS Platforms
• Table 16 : NGS Bioinformatics Workflow
• Table 17 : Sequence Annotation Steps
• Table 18 : NGS Service Providers
• Table 19 : NGS Cost per Sample
• Table 20 : Future Challenges for Implementing NGS
• Table 21 : Global Market for NGS in Drug Development, by Product Type, Through 2028
• Table 22 : Global Market for NGS Instruments in Drug Development, by Region, Through 2028
• Table 23 : Global Market for NGS Consumables in Drug Development, by Region, Through 2028
• Table 24 : Global Market for NGS Services in Drug Development, by Region, Through 2028
• Table 25 : Global Market for NGS in Drug Development, by End User, Through 2028
• Table 26 : Global Market for NGS in Drug Development, by Region, Through 2028
• Table 27 : North American Market for NGS in Drug Development, by Country, Through 2028
• Table 28 : Asia-Pacific Market for NGS in Drug Development, by Country, Through 2028
• Table 29 : European Market for NGS in Drug Development, by Country, Through 2028
• Table 30 : RoW Market for NGS in Drug Development, Through 2028
• Table 31 : Key Focus Areas in ESG Metrics
• Table 32 : Net-Zero GHG Commitments, Major NGS Companies
• Table 33 : ESG Rankings for Major NGS Companies, 2023*
• Table 34 : CDP Scope Card for Major NGS Companies, 2022
• Table 35 : U.S. Patent Related to NGS
• Table 36 : Worldwide Patent Related to NGS
• Table 37 : European Patents Related to NGS
• Table 38 : Chinese Patents Related to NGS
• Table 39 : Japanese Patents Related to NGS
• Table 40 : Global Market Rankings, NGS in Drug Development, by Manufacturer, 2022
• Table 41 : Global Market Rankings for NGS Instruments in Drug Development, by Manufacturer, 2022
• Table 42 : Global Market Rankings for NGS Instruments in Drug Development, by Manufacturer, 2022
• Table 43 : Global Market Rankings for NGS Services in Drug Development, by Manufacturer, 2022
• Table 44 : 10x Genomics: Net Annual Revenue, by Segment, 2020-2022
• Table 45 : 10x Genomics: Net Annual Revenue, by Region/Country, 2020-2022
• Table 46 : 10x Genomics: Products and Services
• Table 47 : Agilent Technologies Inc.: Net Revenue, by Segment, 2020-2022
• Table 48 : Agilent Technologies Inc.: Net Revenue, by Business Segment, 2020-2022
• Table 49 : Agilent Technologies Inc.: Net Revenue, by End Market, 2020-2022
• Table 50 : Agilent Technologies Inc.: Revenue, by Type, 2020-2022
• Table 51 : Agilent Technologies Inc.: Net Revenue, by Region, 2020-2022
• Table 52 : Agilent Technologies Inc.: NGS Products
• Table 53 : BGI: Products and Services
• Table 54 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 55 : Bio-Rad Laboratories Inc.: Company Financials, 2020-2022
• Table 56 : Bio-Rad Laboratories Inc.: Net Revenue, by Business Segment, 2020-2022
• Table 57 : Bio-Rad Laboratories Inc.: Net Revenue, by Region/Country, 2020-2022
• Table 58 : Illumina Inc.: Net Revenue, 2020-2022
• Table 59 : Illumina Inc.: Revenue, by Source, 2021 and 2022
• Table 60 : Illumina Inc.: Net Revenue, by Region, 2020-2022
• Table 61 : Illumina Inc.: Drug Discovery and Development Products
• Table 62 : Oxford Nanopore Technologies: Products and Services
• Table 63 : Oxford Nanopore Technologies: Net Revenue, by Segment, 2020-2022
• Table 64 : Oxford Nanopore Technologies: LSRT Revenue, by Region/Country, 2020-2022
• Table 65 : Pacific Biosciences of California Inc.: Net Revenue, by Segment, 2020-2022
• Table 66 : Pacific Biosciences of California Inc.: Net Revenue, by Region, 2020-2022
• Table 67 : PacBio: Products and Services
• Table 68 : PerkinElmer Inc.: Net Revenue, by Operating Segment, 2020-2022
• Table 69 : PerkinElmer Inc.: Net Revenue, by Business Segment, 2020-2022
• Table 70 : PerkinElmer Inc.: Net Revenue, by Region/Country, 2020-2022
• Table 71 : Qiagen: Financial Revenue, 2020-2022
• Table 72 : Qiagen: Net Revenue, by Customer Class, 2020-2022
• Table 73 : Qiagen: Net Revenue, by Product Group, 2020-2022
• Table 74 : Qiagen: Net Revenue, by Region/Country, 2020-2022
• Table 75 : Qiagen: NGS Products and Services
• Table 76 : Roche Holding AG: Net Revenue, by Business Segment, 2020-2022
• Table 77 : Roche Holding AG: Diagnostics Revenue, by Segment, 2020-2022
• Table 78 : Roche Holding AG: Pharmaceuticals Revenue, by Segment, 2021 and 2022
• Table 79 : Roche Holding AG: Net Revenue, by Region/Country, 2021 and 2022
• Table 80 : Roche Holding AG: NGS Products and Services
• Table 81 : Thermo Fisher Scientific Inc.: Net Revenue, by Segment, 2020-2022
• Table 82 : Thermo Fisher Scientific Inc.: Net Revenue, by Segment, 2020-2022
• Table 83 : Thermo Fisher Scientific Inc.: Net Revenue, by Region, 2020-2022
• Table 84 : Thermo Fisher Scientific Inc.: Products and Services
• Table 85 : Takara Bio Inc.: Net Revenue, by Segment, 2021 and 2022
• Table 86 : Takara Bio Inc.: Net Revenue, by Region/Country, 2020-2022
• Table 87 : Tecan Group Ltd.: Company Financials, 2020 and 2022
• Table 88 : Tecan Group Ltd.: Net Revenue, by Business Segment, 2020-2022
• Table 89 : Tecan Group Ltd.: Net Revenue, by Region, 2022
• Table 90 : Acronyms Used in This Report

List of Figures

• Summary Figure A : Global Market for NGS in Drug Development, by Region, 2020-2028
• Summary Figure B : Global Market Shares of NGS in Drug Development, by Region, 2022
• Figure 1 : Whole Genome Sequencing
• Figure 2 : Number of NGS Tests, Research Activities, Different Global Centers, 2023
• Figure 3 : The Road from NGS to Personalized Medicine
• Figure 4 : Global Market for NGS in Drug Development, by Product Type, 2020-2028
• Figure 5 : Global Market Shares of NGS in Drug Development, by Product Type, 2022
• Figure 6 : Global Market for NGS Instruments in Drug Development, by Region, 2020-2028
• Figure 7 : Global Market Shares of NGS Instruments in Drug Development, by Region, 2022
• Figure 8 : Global Market for NGS Consumables in Drug Development, by Region, 2020-2028
• Figure 9 : Global Market Shares of NGS Consumables in Drug Development, by Region, 2022
• Figure 10 : Global Market for NGS Services in Drug Development, by Region, 2020-2028
• Figure 11 : Global Market Shares of NGS Services in Drug Development, by Region, 2022
• Figure 12 : Global Market for NGS in Drug Development, by End User, 2020-2028
• Figure 13 : Global Market Shares of NGS in Drug Development, by End User, 2022
• Figure 14 : Global Market for NGS in Drug Development, by Region, 2020-2028
• Figure 15 : Global Market Shares of NGS in Drug Development, by Region, 2022
• Figure 16 : North American Market for NGS in Drug Development, by Country, 2020-2028
• Figure 17 : North American Market Shares of NGS in Drug Development, by Country, 2022
• Figure 18 : Asia-Pacific Market for NGS in Drug Development, by Country, 2020-2028
• Figure 19 : Asia-Pacific Market Shares of NGS in Drug Development, by Country, 2022
• Figure 20 : European Market for NGS in Drug Development, by Country, 2020-2028
• Figure 21 : European Market Shares of NGS in Drug Development, by Country, 2022
• Figure 22 : How a Strong ESG Proposition Benefits Businesses
• Figure 23 : Research Communities, Key Sustainable Practices, Research Laboratories
• Figure 24 : Illumina Inc.'s Most Material ESG Issues
• Figure 25 : Emerging Technologies in the NGS Market in Drug Development
• Figure 26 : 10x Genomics: Net Revenue, 2020-2022
• Figure 27 : 10x Genomics: Revenue Share, by Segment, 2022
• Figure 28 : 10x Genomics: Revenue Share, by Region/Country, 2022
• Figure 29 : Agilent Technologies Inc.: Revenue Share, by Segment, 2022
• Figure 30 : Agilent Technologies Inc.: Revenue Share, by Business Segment, 2022
• Figure 31 : Agilent Technologies Inc.: Revenue Share, by End Market, 2022
• Figure 32 : Agilent Technologies Inc.: Revenue Share, by Type, 2022
• Figure 33 : Agilent Technologies Inc.: Revenue Share, by Region, 2022
• Figure 34 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Segment, 2022
• Figure 35 : Bio-Rad Laboratories Inc.: Revenue Share, by Region/Country, 2022
• Figure 36 : Illumina Inc.: Revenue Share, by Segment, 2022
• Figure 37 : Illumina Inc.: Revenue Share, by Segment, 2022
• Figure 38 : Oxford Nanopore Technologies: Net Revenue, 2020-2022
• Figure 39 : Oxford Nanopore Technologies: Revenue Share, by Region/Country, 2022
• Figure 40 : Pacific Biosciences of California Inc.: Revenue Share, by Segment, 2022
• Figure 41 : Pacific Biosciences of California Inc.: Revenue Share, by Region, 2022
• Figure 42 : PerkinElmer Inc.: Revenue Share, by Operating Segment, 2022
• Figure 43 : PerkinElmer Inc.: Revenue Share, by Business Segment, 2022
• Figure 44 : PerkinElmer Inc.: Revenue Share, by Region/Country, 2022
• Figure 45 : Qiagen: Revenue Share, by Segment, 2022
• Figure 46 : Qiagen: Revenue Share, by Customer Class, 2022
• Figure 47 : Qiagen: Revenue Share, by Product Group, 2022
• Figure 48 : Qiagen: Revenue Share, by Region/Country, 2022
• Figure 49 : Roche Holding AG: Revenue Share, by Business Segment, 2022
• Figure 50 : Roche Holding AG: Diagnostics Revenue Share, by Segment, 2022
• Figure 51 : Roche Holding AG: Pharmaceuticals Revenue Share, by Segment, 2022
• Figure 52 : Roche Holding AG: Revenue Share, by Region/Country, 2022
• Figure 53 : Thermo Fisher Scientific Inc.: Net Revenue, 2020-2022
• Figure 54 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2022
• Figure 55 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2022
• Figure 56 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2022
• Figure 57 : Takara Bio Inc.: Net Revenue, 2020-2022
• Figure 58 : Takara Bio Inc.: Revenue Share, by Segment, 2022
• Figure 59 : Takara Bio Inc.: Revenue Share, by Region/Country, 2022
• Figure 60 : Tecan Group Ltd.: Revenue Share, by Business Segment, 2022
• Figure 61 : Tecan Group Ltd.: Revenue Share, by Region, 2022

Highlights:

The global next-generation sequencing (NGS) market in drug development should reach $2.9 billion by 2028 from $1.3 billion in 2023 at a compound annual growth rate (CAGR) of 17.7% for the forecast period of 2023 to 2028.

North American NGS market in drug development is expected to grow from $539.8 million in 2023 to $1.2 billion in 2028 at a CAGR of 18.0% for the forecast period of 2023 to 2028.

Asia-Pacific NGS market in drug development is expected to grow from $311 million in 2023 to $743.6 million in 2028 at a CAGR of 19.0% for the forecast period of 2023 to 2028.

Report Scope:

The scope of this report includes NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS in drug development are given for 2020, 2021, 2022, 2023 and 2028.

This report reviews the NGS technologies and explains why NGS is important in drug development. It then discusses some of the significant research initiatives that impact NGS. The main market-driving forces are also discussed.

This report examines the markets by product type, end user and region. This report provides market data and forecasts for NGS by product type, including instruments, consumables and services for drug development.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the Rest of the World.

BCC Research summarizes the main industry acquisitions and strategic alliances from Jan. 2020, through Dec. 2022, including key alliance trends.

Report Includes:

• 52 data tables and 39 additional tables
• An overview of the global markets for next-generation sequencing on drug development
• Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Highlights of the market potential and characterization of next-generation sequencing on drug development market by product, service, end-user type, and region
• Examination of the key drivers and constraints that will shape the market for next-generation sequencing on drug development and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and subsegments
• Coverage of recent advances, emerging technologies, and developments of the industry
• Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
• Profiles of the key companies of the industry, including 10x Genomics, Bio-Rad Laboratories Inc., Oxford Nanopore Technologies, Qiagen and Takara Bio Inc.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Research Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Introduction
• Technology Background
• Structure and Importance of DNA
• DNA Sequencing Technologies
• Whole Genome Sequencing
• Targeted Resequencing
• ChIP Sequencing
• RNA Sequencing
• Methylation Sequencing
• History of DNA Sequencing
• Sanger Sequencing
• Introduction to Next Generation Sequencing (NGS)
• Advantages of NGS
• Roche 454 Pyrosequencing
• Illumina NGS
• Thermo Fisher Scientific (Life Technologies) NGS
• Sequencing Instruments
• Benchtop Sequencers
• Informatics Technologies
• NGS in Drug Development
• NGS Service Providers

Chapter 4 Market Dynamics

• Market Drivers
• Increasing R&D Activities using NGS technologies
• Increase in Healthcare Expenditure
• Technological Advancements in Sequencing Platforms
• Shift Towards Precision Medicine
• Growing demand of NGS for Designing Individualized Medicine to Cancer Patients
• High Accuracy and Low Cost
• Market Restraints
• Limitations Associated with NGS Technology
• Other Clinical Sequencing Technology Challenges
• Market Opportunities
• Rising R&D in NGS creates lucrative Opportunities for Manufacturers

Chapter 5 NGS in Drug Development by Product Type

• Introduction
• Instruments
• Consumables
• Services

Chapter 6 NGS Market in Drug Development by End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Centers
• Other End Users

Chapter 7 NGS Market in Drug Development by Region

• Market Overview and Discussion
• North America
• Asia-Pacific
• Europe
• Rest of the World

Chapter 8 Sustainability of NGS in Drug Development: An ESG Perspective

• Introduction to ESG
• Sustainability of NGS in Drug Development: An ESG Perspective
• Key ESG Issues
• Consumer Attitudes Towards ESG
• Industry ESG Performance Analysis
• Case Study
• Environment
• Social
• Governance
• Concluding Remarks from BCC

Chapter 9 Emerging Technologies and Developments

• Overview
• Emerging Technologies in the Market
• Application of Artificial Intelligence (AI) in NGS
• Single-Molecule Real-Time Sequencing
• Nanopore Technology
• Microscopy-Based Sequencing

Chapter 10 Patent Analysis

• Introduction
• Patents on NGS by Region

Chapter 11 M&A and Funding Outlook

• M&A Analysis

Chapter 12 Competitive Landscape

• Global Company Ranking
• Global Company Ranking for NGS Instruments in Drug Development
• Global Company Ranking for NGS Consumables in Drug Development
• Global Company Ranking for NGS Services in Drug Development

Chapter 13 Company Profiles

• 10X GENOMICS
• AGILENT TECHNOLOGIES INC.
• BGI (BEIJING GENOMICS INSTITUTE)
• BIO-RAD LABORATORIES INC.
• CD GENOMICS
• ILLUMINA INC.
• INTEGRATED DNA TECHNOLOGIES INC.
• MICRONOMA
• NEW ENGLAND BIOLABS
• OXFORD NANOPORE TECHNOLOGIES
• PACIFIC BIOSCIENCES OF CALIFORNIA INC.
• PERKINELMER INC.
• PROMEGA CORP.
• PSOMAGEN INC.
• PRECISION FOR MEDICINE, FORMERLY APOCELL
• QIAGEN
• ROCHE HOLDING AG
• THERMO FISHER SCIENTIFIC INC.
• TAKARA BIO INC.
• TECAN GROUP LTD.

Chapter 14 Appendix: Acronyms